Loading clinical trials...
Loading clinical trials...
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy (FORTE)
Conditions
Interventions
Fostamatinib
Locations
14
United States
Advanced Research
Tamarac, Florida, United States
Simmons Cancer Institute at Southern Illinois University
Springfield, Illinois, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Saint Agnes Hospital
Baltimore, Maryland, United States
The Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
Maryland Oncology Hematology, P.A
Clinton, Maryland, United States
Start Date
May 18, 2021
Primary Completion Date
November 17, 2022
Completion Date
November 17, 2022
Last Updated
March 15, 2024
NCT05070845
NCT07039422
NCT07007962
NCT07104565
NCT06722235
NCT06107582
Lead Sponsor
Rigel Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions